Roberto Ranieri1,2, Giulio Starnini2,3, Sergio Carbonara2,4, Emanuele Pontali2,5, Guido Leo2,6, Antonio Romano7, Sandro Panese8, Roberto Monarca2,9, Tullio Prestileo10, Giorgio Barbarini11,12, Sergio Babudieri13,14. 1. Azienda Ospedaliera Santi Paolo e Carlo Penitentiary Infectious Diseases Unit, University of Milan, Milan, Italy. 2. SIMSPe-Italian Society for Penitentiary Medicine and Healthcare, v.le San Pietro35/b, 07100, Sassari, Italy. 3. U.O.C. Medicina protetta-Malattie infettive, Viterbo, Italy. 4. Clinic of Infectious Diseases, University of Bari, Bari, Italy. 5. Infectious Disease Unit, Ospedale Galliera, Genoa, Italy. 6. Infectious Disease Unit, Ospedale Amedeo di Savoia, Turin, Italy. 7. Cisanello Hospital, Pisa, Italy. 8. Ospedale dell'Angelo Malattie infettive e Tropicali, Venice, Italy. 9. Ospedale Belcolle, Viterbo, Italy. 10. ARNAS, Ospedale Civico-Benfratelli Palermo, Palermo, Italy. 11. Malattie Infettive e Tropicali IRCCS San Matteo, Università di Pavia, Pavia, Italy. 12. Case Circondariali di Pavia, Voghera e Vigevano, Italy. 13. SIMSPe-Italian Society for Penitentiary Medicine and Healthcare, v.le San Pietro35/b, 07100, Sassari, Italy. babuder@uniss.it. 14. Infectious Disease Unit, University of Sassari, Sassari, Italy. babuder@uniss.it.
Abstract
BACKGROUND: The prevalence of HCV infection is higher among prisoners than in the general population. The introduction of HCV direct-acting antivirals (DAA) holds the potential to improve clinical outcomes also in inmates. However, treatment of hepatitis C in inmates has to face several clinical and logistical issues which are peculiar of prison environment. Recommendations on the management of HCV infection specific for the penitentiary setting in the DAA era remain scant. The Italian Society for Penitentiary Medicine and Healthcare has, therefore, issued these recommendations, to provide clinicians with a guide for the comprehensive management of HCV infection in the restriction setting, taking into account its peculiar characteristics. RESULTS: Dedicated diagnostic and treatment procedures should be established in each prison. In particular, the use of DAAs appears crucial to provide patients with an effective therapeutic option, able to overcome the limitations of IFN-based regimens with a short period of treatment. DAA treatment should be initiated as soon as possible in all eligible subjects with the aim to cure the patient, as well as to limit the transmission of HCV infection both inside the penitentiary system and to the free community, once the inmates ends his/her release. Importantly, efforts should be made to open a discussion with regulatory bodies, to define specific regulations aimed to guarantee wide access to effective therapies of all eligible patients, to optimize the management of and the adherence to the HCV treatment, and to ensure the therapeutic continuity after discharge from prison.
BACKGROUND: The prevalence of HCV infection is higher among prisoners than in the general population. The introduction of HCV direct-acting antivirals (DAA) holds the potential to improve clinical outcomes also in inmates. However, treatment of hepatitis C in inmates has to face several clinical and logistical issues which are peculiar of prison environment. Recommendations on the management of HCV infection specific for the penitentiary setting in the DAA era remain scant. The Italian Society for Penitentiary Medicine and Healthcare has, therefore, issued these recommendations, to provide clinicians with a guide for the comprehensive management of HCV infection in the restriction setting, taking into account its peculiar characteristics. RESULTS: Dedicated diagnostic and treatment procedures should be established in each prison. In particular, the use of DAAs appears crucial to provide patients with an effective therapeutic option, able to overcome the limitations of IFN-based regimens with a short period of treatment. DAA treatment should be initiated as soon as possible in all eligible subjects with the aim to cure the patient, as well as to limit the transmission of HCV infection both inside the penitentiary system and to the free community, once the inmates ends his/her release. Importantly, efforts should be made to open a discussion with regulatory bodies, to define specific regulations aimed to guarantee wide access to effective therapies of all eligible patients, to optimize the management of and the adherence to the HCV treatment, and to ensure the therapeutic continuity after discharge from prison.
Entities:
Keywords:
DAA; HCV; Infection; Management; Penitentiary medicine
Authors: E Sagnelli; G Starnini; C Sagnelli; R Monarca; G Zumbo; E Pontali; A Gabbuti; S Carbonara; R Iardino; O Armignacco; S Babudieri Journal: Eur Rev Med Pharmacol Sci Date: 2012-12 Impact factor: 3.507
Authors: Amanda Weir; Allan McLeod; Hamish Innes; Heather Valerio; Esther J Aspinall; David J Goldberg; Stephen T Barclay; John F Dillon; Ray Fox; Andrew Fraser; Peter C Hayes; Nicholas Kennedy; Peter R Mills; Adrian J Stanley; Celia Aitken; Rory Gunson; Kate Templeton; Alison Hunt; Paul McIntyre; Sharon J Hutchinson Journal: Drug Alcohol Depend Date: 2016-05-28 Impact factor: 4.492
Authors: R Monarca; G Madeddu; R Ranieri; S Carbonara; G Leo; M Sardo; F Choroma; S Casari; D Marri; A A Muredda; F A Nava; S Babudieri Journal: BMC Infect Dis Date: 2015-12-10 Impact factor: 3.090
Authors: Nadine Kronfli; Roy Nitulescu; Joseph Cox; Erica Em Moodie; Alexander Wong; Curtis Cooper; John Gill; Sharon Walmsley; Valérie Martel-Laferrière; Mark W Hull; Marina B Klein Journal: J Int AIDS Soc Date: 2018-11 Impact factor: 5.396
Authors: Vito Fiore; Elena Rastrelli; Giordano Madeddu; Roberto Ranieri; Andrea De Vito; Ruggero Giuliani; Giulio Di Mizio; Matteo Bolcato; Giuseppe De Matteis; Anna Maria Ialungo; Serena Dell'Isola; Giulio Starnini; Sergio Babudieri Journal: BMC Infect Dis Date: 2022-07-07 Impact factor: 3.667
Authors: Rob Bielen; Samya R Stumo; Rachel Halford; Klára Werling; Tatjana Reic; Heino Stöver; Geert Robaeys; Jeffrey V Lazarus Journal: Harm Reduct J Date: 2018-05-11